Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV‐related condition in the real life practice

Interferon‐free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis

“…Collectively, these data emphasise the need to identify cryoglobulinaemic patients and to treat them as soon as possible to obtain the best virological and clinical benefits. This is only feasible when a correct diagnostic approach to HCV patients has been used, so as not to underestimate the condition …”

Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis

“…Symptomatic cryoglobulinemia vasculitis (CryoVas), an immune complex-mediated systemic vasculitis that mainly affects small-and medium-sized vessels, has been observed in about 15% of hepatitis C virus (HCV)-infected patients (1)(2)(3)(4)(5)(6). HCV-associated CryoVas (HCV-CryoVas) is a severe disease with an estimated 5-year mortality rate of 25% (1,3,7).…”

Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis

“…CryoVas and mixed cryoglobulins are present in 25-45% of patients with HCV [4,5]. A minority of patients with HCV and mixed cryoglobulins exhibit symptomatic CryoVas, which is present in approximately 10-35% of patients who are HCV-positive and cryoglobulin-positive [4,5].…”

“…CryoVas and mixed cryoglobulins are present in 25-45% of patients with HCV [4,5]. A minority of patients with HCV and mixed cryoglobulins exhibit symptomatic CryoVas, which is present in approximately 10-35% of patients who are HCV-positive and cryoglobulin-positive [4,5]. CryoVas has a variety of clinical features, which range from rare to highly prevalent, affecting mainly the skin, joints, peripheral nervous system and kidneys (Table 1).…”